Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report

No information is reported that could enable the patient to be identified; therefore, no patient consent to report this case was required.This manuscript was prepared according to CARE guidelines. Case reportA 70-year-old, non-smoker man with overweight (BMI 26.4 kg/m 2 ) and a medical history of hypertension and AbstractNon-alcoholic fatty liver disease (NAFLD) is one of the most frequent chronic liver disorders worldwide.It is closely associated with metabolic syndrome components, including type 2 diabetes, hyperlipidaemia and obesity.To date, no effective drug treatment is available for NAFLD but several clinical trials suggested that silymarin, the active milk thistle extract, has well-documented antioxidant and hepatoprotective properties.In this case report, silymarin 140 mg twice daily decreased liver enzyme activity with a good safety profile in a patient with NAFLD and overweight, supporting silymarin as a promising supportive intervention aimed at normalizing liver activity in NAFLD.This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/ current-clinical-use-of-silymarin-in-the-treatment- of-toxic-liver-diseases-a-case-series Keywords: case report, deranged liver enzymes, liver function, non-alcoholic fatty liver disease, silymarin. CitationChantarojanasiri T. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report.